JP2025515092A5 - - Google Patents

Info

Publication number
JP2025515092A5
JP2025515092A5 JP2024564920A JP2024564920A JP2025515092A5 JP 2025515092 A5 JP2025515092 A5 JP 2025515092A5 JP 2024564920 A JP2024564920 A JP 2024564920A JP 2024564920 A JP2024564920 A JP 2024564920A JP 2025515092 A5 JP2025515092 A5 JP 2025515092A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
acid sequence
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024564920A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515092A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/065591 external-priority patent/WO2023215674A1/en
Publication of JP2025515092A publication Critical patent/JP2025515092A/ja
Publication of JP2025515092A5 publication Critical patent/JP2025515092A5/ja
Pending legal-status Critical Current

Links

JP2024564920A 2022-05-03 2023-04-10 リンパ腫の処置方法 Pending JP2025515092A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263337941P 2022-05-03 2022-05-03
US63/337,941 2022-05-03
US202263340909P 2022-05-11 2022-05-11
US63/340,909 2022-05-11
PCT/US2023/065591 WO2023215674A1 (en) 2022-05-03 2023-04-10 Methods for treating lymphoma

Publications (2)

Publication Number Publication Date
JP2025515092A JP2025515092A (ja) 2025-05-13
JP2025515092A5 true JP2025515092A5 (https=) 2026-04-17

Family

ID=86378472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024564920A Pending JP2025515092A (ja) 2022-05-03 2023-04-10 リンパ腫の処置方法

Country Status (11)

Country Link
US (1) US20250388691A1 (https=)
EP (1) EP4518975A1 (https=)
JP (1) JP2025515092A (https=)
KR (1) KR20250019746A (https=)
CN (1) CN119546335A (https=)
AU (1) AU2023264582A1 (https=)
CA (1) CA3256548A1 (https=)
CL (2) CL2024003328A1 (https=)
IL (1) IL316747A (https=)
MX (1) MX2024013531A (https=)
WO (1) WO2023215674A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
BR112017023943A2 (pt) * 2015-05-08 2018-07-31 Xencor, Inc. anticorpos heterodimêricos que ligam cd3 e antígenos de tumor
WO2018002031A1 (en) * 2016-06-27 2018-01-04 Morphosys Ag Anti-cd19 antibody formulations
CN112794916B (zh) * 2021-04-08 2021-08-10 正大天晴药业集团南京顺欣制药有限公司 三特异性抗原结合构建体及构建方法和应用

Similar Documents

Publication Publication Date Title
JP2025515092A5 (https=)
JP2021523122A5 (https=)
RU2006120950A (ru) Антитело к cd40: препарат и способы
JP2019517549A5 (https=)
RU2679119C2 (ru) Лечение неопластических заболеваний
JP2014114288A5 (https=)
US20220332832A1 (en) Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
JP2019532970A5 (https=)
JP2023501375A5 (https=)
WO2023061472A1 (zh) 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途
JP2024520901A5 (https=)
JP2022529929A5 (https=)
JP2023502876A5 (https=)
JP2003505432A (ja) 抗ep−cam抗体と化学療法剤との組合せ
US20240043543A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
CN105813637A (zh) 用于治疗慢性疲劳综合征的可溶性鸟苷酸环化酶的激活剂或刺激剂
CN119055787A (zh) 抗her2抗体-药物偶联物在治疗癌症中的用途
JP2021518348A5 (https=)
JP2024528877A5 (https=)
JP2023546504A5 (https=)
TW202034925A (zh) Cdk4/6抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途
JP2022513072A5 (https=)
JP2025526402A5 (https=)
AU2019364239B2 (en) Pan-ELR+ CXC chemokine antibodies for the treatment of hidradenitis suppurativa
JP2023530997A5 (https=)